On Monday, Cardinal Health experienced a drop in share prices during intraday trading after announcing that its contracts with OptumRX, the pharmacy benefits provider of UnitedHealth Group, will not be renewed. Despite this setback, the company remains optimistic about its outlook for the year and beyond.
Cardinal Health reaffirmed its 2024 adjusted earnings per share guidance and long-term profit growth targets for its Pharmaceutical and Specialty Solutions segments. CEO Jason Hollar expressed confidence in the resilience and value proposition of the company’s business.
Sales to OptumRX accounted for 16% of Cardinal Health’s revenue in 2023. The agreements with OptumRX are set to expire at the end of June. To offset this impact, Cardinal Health expects to grow through new customer acquisitions, specialty growth, and other strategic measures.
Shares of Cardinal Health experienced a 5% decline to $102.78 during intraday trading on Monday. Despite this challenge, the company is committed to navigating it and continuing to deliver value to its customers and shareholders.
Starting on Tuesday, Business Loop 70 in Columbia will be closed for up to 36…
In recent years, airlines have faced increasing competition and pressure to offer unique and memorable…
Yaroslava Mahuchikh from Ukraine set a new world record in high jump during a Diamond…
At the Paris Diamond League, Laura Muir broke the British 1500m record with a time…
Pearl Jam returned to the stage in Barcelona on Saturday night, after postponing three shows…
Carlos Alcaraz is one step closer to defending his Wimbledon title after a tough win…